PMID: 9634499Jun 20, 1998Paper

Radiation dose response for subclinical metastases

Seminars in Radiation Oncology
H R Withers, R Suwinski

Abstract

The development of adjuvant therapies for subclinical metastases has been empiric. Decades of experience showed that 45 to 50 Gy resulted in high control rates for subclinical lymph node involvement.1 By analogy with the response of macroscopic tumors, in which doses below a threshold yield no benefit, it was commonly believed that doses lower than 40 to 50 Gy would not be useful in elective treatment of subclinical disease. Biological phenomena, such as presumed metastatic tumor cell burden and growth rate of micrometastases, which could guide the oncologist, had little or no role in the empirical development of adjuvant cytotoxic therapies. In this article, some assumptions regarding the biology of subclinical metastases are discussed and examined in the light of treatment responses reported from clinical experience. In particular, the importance of early initiation of adjuvant therapy can be appreciated as well as the significant reductions in the incidence of metastases that can be achieved even when doses less than 45 to 50 Gy have to be accepted if necessitated by normal tissue tolerance.

References

Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H SuitJ T Efird
Jan 15, 1995·International Journal of Radiation Oncology, Biology, Physics·H R WithersJ M Taylor
Dec 30, 1998·International Journal of Radiation Oncology, Biology, Physics·R SuwinskiH R Withers

❮ Previous
Next ❯

Citations

Apr 25, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Vicente Pedraza Muriel
Jan 31, 2004·International Journal of Radiation Oncology, Biology, Physics·H Rodney Withers, Karin Haustermans
Dec 4, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·R ArriagadaM R Baeza
May 23, 2002·International Journal of Radiation Oncology, Biology, Physics·Rodrigo HeppEugenio Suarez
May 10, 2003·International Journal of Radiation Oncology, Biology, Physics·Rafal SuwinskiBoguslaw Maciejewski
Jun 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Susan W LeeWalter K Kinney
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Jesus Gonzalez BosquetKarl C Podratz
Jun 10, 2008·The Cancer Journal·William A Castrucci, Jonathan P S Knisely
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B Sorbe
Oct 28, 2005·BMC Cancer·Wayne S Kendal
Dec 30, 1998·International Journal of Radiation Oncology, Biology, Physics·R SuwinskiH R Withers
Oct 23, 2014·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Marzena Gawkowska-SuwińskaRafał Tarnawski
Mar 14, 2003·Seminars in Oncology·Maureen F Zakowski
May 29, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Mechthild KrauseMichael Baumann
Feb 25, 2015·Annals of Surgical Oncology·Lori M van RoozendaalMarjolein L Smidt
May 30, 2006·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Rafal SuwinskiJacek Starzewski
Mar 28, 2006·Seminars in Radiation Oncology·H Rodney Withers, Steve P Lee
Feb 24, 2001·Clinical Oncology : a Journal of the Royal College of Radiologists·N ShahS Dische
Sep 10, 2013·The Breast : Official Journal of the European Society of Mastology·Tejinder KatariaN Karthikeyan
Jun 21, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Al-MamganiM W M van den Brekel
Apr 17, 2012·Expert Review of Anticancer Therapy·Joanna Socha, Lucyna Kępka
Dec 22, 1999·American Journal of Clinical Oncology·A R Kagan, T L Morgan
Oct 8, 2003·International Journal of Radiation Biology·R Suwinski, H R Withers
Oct 11, 2005·Journal of Neuro-oncology·R SoffiettiR Rudà
Jan 7, 2021·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M SchmittG Noël
Jul 23, 2021·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Martin SchmittGeorges Noel
Aug 5, 2008·Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS·R R Clark, D S Soutar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Radiation Oncology, Biology, Physics
H R WithersJ M Taylor
International Journal of Radiation Oncology, Biology, Physics
R SuwinskiH R Withers
International Journal of Radiation Oncology, Biology, Physics
H R WithersJ M Taylor
The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi
S SasanoS Nitta
© 2022 Meta ULC. All rights reserved